Relmada Therapeutics Announces $100M Stock Offering

Relmada Therapeutics ( (RLMD) ) has shared an announcement.

On November 4, 2025, Relmada Therapeutics announced the pricing of a $100 million underwritten offering of common stock and pre-funded warrants. The proceeds from this offering are intended to support working capital, corporate purposes, and further development of product candidates, as well as potential investments or acquisitions in synergistic technologies. The offering is expected to close on November 5, 2025, and includes participation from notable investors such as Janus Henderson Investors and OrbiMed.

The most recent analyst rating on (RLMD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.

Spark’s Take on RLMD Stock

According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.

Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.

To see Spark’s full report on RLMD stock, click here.

More about Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

Average Trading Volume: 1,087,404

Technical Sentiment Signal: Hold

Current Market Cap: $91.94M

For a thorough assessment of RLMD stock, go to TipRanks’ Stock Analysis page.